Cybin D/B/A Helus Pharma (HELP) Stock Analysis 2026

Cybin D/B/A Helus Pharma doesn't carry a meaningful trailing P/E right now, generates $-82.4M in free cash flow, hasn't disclosed a debt/equity ratio, and converts shareholder equity into profit at a -86.9% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Wall Street analysts covering Cybin D/B/A Helus Pharma currently haven't converged on a clear consensus rating, with a mean 12-month price target of $41.49. Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

HELP is currently in a mixed technical position. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

In-depth reports on companies operating alongside HELP — business models, bull and bear cases, and the metrics that matter.